KJHP
SEEL

K.J. Harrison & Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

K.J. Harrison & Partners’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed -$20K – 263
2020
Q2 		$20K Buy
+5
New +$16.6K 0.01% 194

Other funds holding SEEL

UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

K.J. Harrison & Partners's SEEL Position: Q3 2020 in Review

K.J. Harrison & Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2020, closing a stake of 5 shares — an estimated $20K sold.

K.J. Harrison & Partners first reported a position in SEEL in Q2 2020 and held it in 1 quarter. The position peaked at $20K in Q2 2020. 24 funds tracked by Wall St. Rank hold SEEL as of Q3 2020.

  • K.J. Harrison & Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • K.J. Harrison & Partners sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $20K.
  • K.J. Harrison & Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • K.J. Harrison & Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $20K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on K.J. Harrison & Partners's 13F filing for Q3 2020, filed 9 Nov 2020.